ClinicalTrials.gg
CompletedNCT02780167Updated May 2, 2019Results posted

Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis

A Phase 2 interventional study of PF-04965842 and PF-04965842 in Atopic Dermatitis, sponsored by Pfizer. Completed at 64 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-05-02.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
269
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing abrocitinib in Dermatitis, Atopic — 5 open to participants now, 5 under way, 2 of them phase 3. abrocitinib · Dermatitis, Atopic.

Enrollment
9th of 20
269 · median 150
Started
2016
the only one that year
Phase 2
4 of 20
1 open now
Registered
1st of 20
by date
Lead sponsor
15 of 20
Pfizer

Among the 20 studies testing abrocitinib in Dermatitis, Atopic, this one is the 9th largest by enrollment, is the only one that started in 2016, is one of 4 in phase 2, and was the 1st registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

5 of the 20 studies testing abrocitinib in Dermatitis, Atopic are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About abrocitinib

abrocitinib: first FDA approval 2022 (CIBINQO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing abrocitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

Study B7451006 is a Phase 2b POC study which is planned to assess four PF 04965842 once daily (QD) doses (10, 30, 100, 200 mg) relative to placebo over 12 weeks to characterize the efficacy and safety of PF 04965842 in subjects with moderate to severe AD. The objectives of the study are to demonstrate the efficacy of PF 04965842 by showing improvement in disease severity in patients with moderate to severe AD as measured by the Investigator's Global Assessment (IGA) and Eczema Area and Severity Index (EASI) scores, and safety to support further clinical development of PF 04965842.

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • Phase 2
  • randomized
  • double-blind
  • placebo
  • atopic dermatitis
  • safety
  • efficacy
  • JAK
  • janus kinase
  • moderate
  • severe
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects between 18 75 years of age, inclusive, at time of .
  • Must have the following atopic dermatitis criteria:

    1. Have a clinical diagnosis of chronic atopic dermatitis (also known as atopic eczema) for at least 1 year prior to Day 1 and has confirmed atopic dermatitis (Hanifin and Rajka criteria of AD refer to Appendix 2) at the Screening visit.
    2. Have inadequate response to treatment with topical medications given for at least 4 weeks, or for whom topical treatments are otherwise medically inadvisable (eg, because of important side effects or safety risks) within 12 months of the first dose of study drug.
    3. Moderate to severe AD (affected BSA >=10 %, IGA >=3, and EASI >=12 at the screening and baseline visits).

Exclusion criteria

Exclusion Criteria:

  • History of (HIV) or positive HIV serology at screening,
  • Infected with or viruses.
  • Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB)
  • Have received any of the following treatment regiments specified in the timeframes outlined below:

Within 6 months of first dose of study drug: Any cell depleting agents Within 12 weeks of first dose of study drug: Any studies with JAK inhibitors; Other biologics Within 8 weeks of first dose of study drug: Participation in other studies involving drug(s) Within 6 weeks of first dose of study drug: Have been vaccinated with live or attenuated .

Within 4 weeks of first dose of study drug: Use of oral immune suppressants; Phototherapy (NB UVB) or broad band phototherapy; Regular use (more than 2 visits per week) of a tanning booth/parlor.

Within 1 week of first dose of study drug: Topical treatments that could affect atopic dermatitis; Herbal medications with unknown properties or known beneficial effects for AD.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
269 participants (actual)

Study arms

  • Experimental
    Cohort 1

    10 mg of PF-04965842 QD

    Drug: PF-04965842

  • Experimental
    Cohort 2

    30 mg of PF-04965842 QD

    Drug: PF-04965842

  • Experimental
    Cohort 3

    100 mg of PF-04965842 QD

    Drug: PF-04965842

  • Experimental
    Cohort 4

    200 mg of PF-04965842 QD

    Drug: PF-04965842

  • Placebo comparator
    Cohort 5

    placebo QD

    Drug: Placebo

Interventions

  • 10 mg of PF-04965842 QD for 12 weeks

  • 30 mg of PF-04965842 QD for 12 weeks

  • 100 mg of PF-04965842 QD for 12 weeks

  • 200 mg of PF-04965842 QD for 12 weeks

  • DrugPlacebo

    Placebo QD for 12 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving the Investigator's Global Assessment (IGA) for Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 12

    The IGA score quantifies the severity of participants' atopic dermatitis (AD). Scores range from 0 to 4 and correspond to a category (clear, almost clear, mild, moderate and severe, respectively).

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Percent Change From Baseline in the Eczema Area and Severity Index (EASI) at Week 12

    The EASI quantifies the severity of participants' AD based on both severity of lesion clinical signs and the percent of body surface area (BSA) affected. EASI is a composite scoring by the AD clinical evaluator of the degree of erythema, induration/population, excoriation, and lichenification (each scored separately) for each of 4 regions, with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD.

    Time frame: Baseline and Week 12

  2. Percentage of Participants Achieving the IGA for Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at All Scheduled Time Points Except Week 12

    The IGA score quantifies the severity of participants' AD. Scores range from 0 to 4 and correspond to a category (clear, almost clear, mild, moderate and severe, respectively).

    Time frame: Baseline and all scheduled time points except Week 12, including Weeks 1, 2, 4, 6, 8, 13, 14, 16.

  3. Percentage of Participants Achieving >=2 Points Improvement in the IGA From Baseline at All Scheduled Time Points

    The IGA score quantifies the severity of participants' AD. Scores range from 0 to 4 and correspond to a category (clear, almost clear, mild, moderate and severe, respectively).

    Time frame: Baseline and all scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 13, 14, 16

  4. Percent Change From Baseline in the EASI Total Score at All Scheduled Time Points Except Week 12.

    The EASI quantifies the severity of participants' AD based on both severity of lesion clinical signs and the percent of BSA affected. EASI is a composite scoring by the AD clinical evaluator of the degree of erythema, induration/population, excoriation, and lichenification (each scored separately) for each of 4 regions, with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD.

    Time frame: Baseline and all scheduled time points except Week 12, including Weeks 1, 2, 4, 6, 8, 13, 14, 16

  5. Percentage of Participants Achieving >=3 Points Improvement in the Pruritus Numerical Rating Scale (NRS) From Baseline at All Scheduled Time Points

    The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "worst itching due to AD over the past 24 hours" on a NRS anchored by the terms "no itching" (0) and "worst possible itching" (10). The frequency of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "frequency of itching due to AD over the past 24 hours" on a NRS anchored by the terms "never/no itching" (0) and "always/constant itching" (10).

    Time frame: Baseline and all scheduled time points, including Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 29, 43, 57, 85, 99, 113

  6. Percentage of Participants Achieving >=4 Points Improvement in the Pruritus NRS From Baseline at All Scheduled Time Points

    The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "worst itching due to AD over the past 24 hours" on a NRS anchored by the terms "no itching" (0) and "worst possible itching" (10). The frequency of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "frequency of itching due to AD over the past 24 hours" on a NRS anchored by the terms "never/no itching" (0) and "always/constant itching" (10).

    Time frame: Baseline and all scheduled time points, including Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 29, 43, 57, 85, 99, 113

  7. Time to Achieving >=3 Points Improvement in NRS

    The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "worst itching due to AD over the past 24 hours" on a NRS anchored by the terms "no itching" (0) and "worst possible itching" (10). The frequency of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "frequency of itching due to AD over the past 24 hours" on a NRS anchored by the terms "never/no itching" (0) and "always/constant itching" (10).

    Time frame: Baseline till Week 16

  8. Time to Achieving >=4 Points Improvement in NRS

    The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "worst itching due to AD over the past 24 hours" on a NRS anchored by the terms "no itching" (0) and "worst possible itching" (10). The frequency of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "frequency of itching due to AD over the past 24 hours" on a NRS anchored by the terms "never/no itching" (0) and "always/constant itching" (10).

    Time frame: Baseline till Week 16

  9. Percent Change From Baseline in the Pruritus NRS From Baseline at All Scheduled Time Points

    The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "worst itching due to AD over the past 24 hours" on a NRS anchored by the terms "no itching" (0) and "worst possible itching" (10). The frequency of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "frequency of itching due to AD over the past 24 hours" on a NRS anchored by the terms "never/no itching" (0) and "always/constant itching" (10).

    Time frame: Baseline and all scheduled time points, including Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 29, 43, 57, 85, 99, 113

  10. Change From Baseline in Pruritus NRS Score at All Scheduled Time Points

    The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "worst itching due to AD over the past 24 hours" on a NRS anchored by the terms "no itching" (0) and "worst possible itching" (10). The frequency of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "frequency of itching due to AD over the past 24 hours" on a NRS anchored by the terms "never/no itching" (0) and "always/constant itching" (10).

    Time frame: Baseline and all scheduled time points, including Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 29, 43, 57, 85, 99, 113

  11. Percentage of Participants Achieving a >=50% Improvement in the EASI Total Score (EASI50) at All Scheduled Time Points

    The EASI quantifies the severity of participants' AD based on both severity of lesion clinical signs and the percent of BSA affected. EASI is a composite scoring by the AD clinical evaluator of the degree of erythema, induration/population, excoriation, and lichenification (each scored separately) for each of 4 regions, with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD.

    Time frame: All scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 13, 14, 16

  12. Percentage of Participants Achieving a >=75% Improvement in the EASI Total Score (EASI75) at All Scheduled Time Points

    The EASI quantifies the severity of participants' AD based on both severity of lesion clinical signs and the percent of BSA affected. EASI is a composite scoring by the AD clinical evaluator of the degree of erythema, induration/population, excoriation, and lichenification (each scored separately) for each of 4 regions, with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD.

    Time frame: All scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 13, 14, 16

  13. Percentage of Participants Achieving a >=90% Improvement in the EASI Total Score (EASI90) at All Scheduled Time Points

    The EASI quantifies the severity of participants' AD based on both severity of lesion clinical signs and the percent of BSA affected. EASI is a composite scoring by the AD clinical evaluator of the degree of erythema, induration/population, excoriation, and lichenification (each scored separately) for each of 4 regions, with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD.

    Time frame: All scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 13, 14, 16

  14. Change From Baseline in Affected BSA at All Scheduled Time Points

    BSA Efficacy is derived from the sum of the BSA in handprints across 4 body regions assessed as part of the EASI assessment. Handprint refers to that of each individual participant for their own measurement. The BSA Efficacy ranges from 0 to 100%, with higher values representing greater severity of AD. Since the scalp, palms, and soles are excluded from the BSA (Efficacy) assessment, the maximum possible value is less than 100%.

    Time frame: Baseline and all scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 13, 14, 16

  15. Change From Baseline in Scoring Atopic Dermatitis (SCORAD) at All Scheduled Time Points

    SCORAD is a validated scoring index for AD, which combines extent (0-100), severity (0-18), and subjective symptoms (0-20) based on pruritus and sleep loss, each scored (0-10). Extent, denoted as A, is measured by BSA affected by AD as a percentage of the whole BSA. The score for each body region is added up to determine A (maximum of 100%). Severity, denoted as B, consists of the severity of several signs. Each is assessed as none(0), mild(1), moderate(2) or severe(3). The severity scores are added together to give B (maximum of 18). Subjective symptoms, denoted as C, are each scored by the subject or caregiver using a numeric rating scale (NRS) where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness). These scores are added to give 'C' (maximum of 20). The SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103). Higher values of SCORAD represent worse outcome.

    Time frame: Baseline and all scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 13, 14, 16

  16. Percent Change From Baseline in SCORAD at All Scheduled Time Points

    SCORAD is a validated scoring index for AD, which combines extent (0-100), severity (0-18), and subjective symptoms (0-20) based on pruritus and sleep loss, each scored (0-10). Extent, denoted as A, is measured by BSA affected by AD as a percentage of the whole BSA. The score for each body region is added up to determine A (maximum of 100%). Severity, denoted as B, consists of the severity of several signs. Each is assessed as none(0), mild(1), moderate(2) or severe(3). The severity scores are added together to give B (maximum of 18). Subjective symptoms, denoted as C, are each scored by the subject or caregiver using a numeric rating scale (NRS) where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness). These scores are added to give 'C' (maximum of 20). The SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103). Higher values of SCORAD represent worse outcome.

    Time frame: Baseline and all scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 13, 14, 16

  17. Percentage of Participants Achieving a >=50% Improvement in SCORAD (SCORAD50) From Baseline at All Scheduled Time Points

    SCORAD is a validated scoring index for AD, which combines extent (0-100), severity (0-18), and subjective symptoms (0-20) based on pruritus and sleep loss, each scored (0-10). Extent, denoted as A, is measured by BSA affected by AD as a percentage of the whole BSA. The score for each body region is added up to determine A (maximum of 100%). Severity, denoted as B, consists of the severity of several signs. Each is assessed as none(0), mild(1), moderate(2) or severe(3). The severity scores are added together to give B (maximum of 18). Subjective symptoms, denoted as C, are each scored by the subject or caregiver using a numeric rating scale (NRS) where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness). These scores are added to give 'C' (maximum of 20). The SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103). Higher values of SCORAD represent worse outcome.

    Time frame: Baseline and all scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 13, 14, 16

  18. Percentage of Participants Achieving a >=75% Improvement in SCORAD (SCORAD75) From Baseline at All Scheduled Time Points

    SCORAD is a validated scoring index for AD, which combines extent (0-100), severity (0-18), and subjective symptoms (0-20) based on pruritus and sleep loss, each scored (0-10). Extent, denoted as A, is measured by BSA affected by AD as a percentage of the whole BSA. The score for each body region is added up to determine A (maximum of 100%). Severity, denoted as B, consists of the severity of several signs. Each is assessed as none(0), mild(1), moderate(2) or severe(3). The severity scores are added together to give B (maximum of 18). Subjective symptoms, denoted as C, are each scored by the subject or caregiver using a numeric rating scale (NRS) where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness). These scores are added to give 'C' (maximum of 20). The SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103). Higher values of SCORAD represent worse outcome.

    Time frame: Baseline and all scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 13, 14, 16

  19. Number of Participants With Treatment-emergent Adverse Events (AEs)

    An AE was any untoward medical occurrence in a subject administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Treatment-emergent AEs were events that occurred between the first dose of study drug and the subject's last visit (Week 16) that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Baseline till Week 16

  20. Number of Participants With Specific Clinical Laboratory Abnormalities (Anemia, Neutropenia, Thrombocytopenia, Lymphopenia, Lipid Profile, Liver Function Tests (LFTs)

    Time frame: Baseline up to Week 16

  21. Percentage of Participants With Patient Global Assessment (PtGA) of AD of Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at All Scheduled Time Points

    The PtGA asked the participant to evaluate the overall cutaneous disease at that point in time on a single-item, 5-point scale. The same category labels used in the Physician's Global Assessment was used for the PtGA, ie, "severe (4)", "moderate (3)", "mild (2)","almost clear (1)", and "clear (0)". The PtGA was completed as per schedule of activities.

    Time frame: Baseline and all scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 14, 16

  22. Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at All Scheduled Time Points

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess participant health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). It has been extensively used in clinical trials for AD. The DLQI is a psychometrically valid and reliable instrument that has been translated into several languages, and the DLQI total scores have been shown to be responsive to change. The minimally important difference for the DLQI has been estimated as a 2-5 point change from baseline. Each item is scored as "very much (3)", "a lot (2)", "a little (1)" and "not at all (0)". The score can range from 0 to 30. The higher values represent the worse dermatology life quality.

    Time frame: Baseline and all scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 14, 16

  23. Change From Baseline in Patient Oriented Eczema Measure (POEM) at All Scheduled Time Points

    The POEM is a 7-item patient reported outcome (PRO) measure used to assess the impact of AD over the past week. Each item is scored as "no days (0)", "1-2 days (1)", "3-4 days (2)", "5-6 days (3)" and "every day (4)". The score ranges from 0 to 28. The higher values represent more severe AD.

    Time frame: Baseline and all scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 14, 16

  24. Change From Baseline in the Hospital and Anxiety Depression Scale (HADS) at All Scheduled Time Points

    The HADS is a 14-item PRO measure used to detect states of anxiety and depression over the past week. The HADS was completed as per schedule of activities. Seven of the items relate to anxiety and seven relate to depression. Each item is scored from 0 to 3 which means a person can score between 0 to 21 for either anxiety or depression. Higher values represent worse outcome.

    Time frame: Baseline and all scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 14, 16

07

Results

Posted May 16, 2018

Participant flow

Participant flow — Overall Study
MilestonePlaceboPF-04965842 10mg QDPF-04965842 30mg QDPF-04965842 100mg QDPF-04965842 200mg QD
Started5649515655
Completed2827273738
Not completed2822241917
Withdrew: Adverse event988128
Withdrew: Lack of efficacy65610
Withdrew: Lost to follow-up20100
Withdrew: Does not meet entrance criteria00100
Withdrew: No longer meets eligibility criteria00011
Withdrew: Protocol violation55112
Withdrew: Withdrawal by subject64434
Withdrew: Other00312

Outcome measures

PrimaryPercentage of Participants Achieving the Investigator's Global Assessment (IGA) for Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 12

The IGA score quantifies the severity of participants' atopic dermatitis (AD). Scores range from 0 to 4 and correspond to a category (clear, almost clear, mild, moderate and severe, respectively).

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percentage of participants
Percentage of Participants Achieving the Investigator's Global Assessment (IGA) for Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 12
percentage of participantsPlaceboPF-04965842 10mg QDPF-04965842 30mg QDPF-04965842 100mg QDPF-04965842 200mg QD
Percentage of Participants Achieving the Investigator's Global Assessment (IGA) for Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 126.3 ± 2.558.2 ± 2.3212.3 ± 2.8827.8 ± 5.0744.5 ± 6.92
Statistical analysis
  • Placebo vs PF-04965842 10mg QD · Emax model · p = 0.1210 · Estimate difference: 1.8 · 95% CI -0.7 to 4.4Test group: PF-04965842 10 mg QD, Reference group: Placebo.
  • Placebo vs PF-04965842 30mg QD · Emax model · p = 0.1065 · Estimate difference: 6.0 · 95% CI -1.8 to 13.8Test group: PF-04965842 30 mg QD, Reference group: Placebo.
  • Placebo vs PF-04965842 100mg QD · Emax model · p = 0.0184 · Estimate difference: 21.5 · 95% CI 5.5 to 37.6Test group: PF-04965842 100 mg QD, Reference group: Placebo.
  • Placebo vs PF-04965842 200mg QD · Emax model · p = 0.0032 · Mean difference (final values): 38.2 · 95% CI 19.7 to 56.6Test group: PF-04965842 200 mg QD, Reference group: Placebo.
SecondaryPercent Change From Baseline in the Eczema Area and Severity Index (EASI) at Week 12

The EASI quantifies the severity of participants' AD based on both severity of lesion clinical signs and the percent of body surface area (BSA) affected. EASI is a composite scoring by the AD clinical evaluator of the degree of erythema, induration/population, excoriation, and lichenification (each scored separately) for each of 4 regions, with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in the Eczema Area and Severity Index (EASI) at Week 12
percent changePlaceboPF-04965842 10mg QDPF-04965842 30mg QDPF-04965842 100mg QDPF-04965842 200mg QD
Percent Change From Baseline in the Eczema Area and Severity Index (EASI) at Week 12-35.22 ± 6.572-31.13 ± 7.090-40.73 ± 6.823-59.04 ± 6.212-82.57 ± 6.161
Statistical analysis
  • Placebo vs PF-04965842 10mg QD · Mixed Models Analysis · p = 0.6731 · Ls mean difference: 4.08 · 90% CI -11.88 to 20.05Test group: PF-04965842 10 mg QD, Reference group: Placebo.
  • Placebo vs PF-04965842 30mg QD · Mixed Models Analysis · p = 0.5610 · Ls mean difference: -5.52 · 90% CI -21.16 to 10.13Test group: PF-04965842 30 mg QD, Reference group: Placebo.
  • Placebo vs PF-04965842 100mg QD · Mixed Models Analysis · p = 0.0091 · Ls mean difference: -23.82 · 90% CI -38.76 to -8.88Test group: PF-04965842 100 mg QD, Reference group: Placebo.
  • Placebo vs PF-04965842 200mg QD · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -47.35 · 90% CI -62.23 to -32.47Test group: PF-04965842 200 mg QD, Reference group: Placebo.
SecondaryPercentage of Participants Achieving the IGA for Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at All Scheduled Time Points Except Week 12

The IGA score quantifies the severity of participants' AD. Scores range from 0 to 4 and correspond to a category (clear, almost clear, mild, moderate and severe, respectively).

Time frame:
Baseline and all scheduled time points except Week 12, including Weeks 1, 2, 4, 6, 8, 13, 14, 16.
Reported as:
Number · percentage of participants
Percentage of Participants Achieving the IGA for Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at All Scheduled Time Points Except Week 12
percentage of participantsPlaceboPF-04965842 10mg QDPF-04965842 30mg QDPF-04965842 100mg QDPF-04965842 200mg QD
Week 10.02.12.01.83.7
Week 23.66.16.03.611.5
Week 41.88.28.016.440.7
Week 614.514.314.012.740.7
Week 85.58.212.016.441.5
Week 1310.020.712.923.726.7
Week 1418.810.73.412.515.9
Week 1610.723.17.413.918.4
SecondaryPercentage of Participants Achieving >=2 Points Improvement in the IGA From Baseline at All Scheduled Time Points

The IGA score quantifies the severity of participants' AD. Scores range from 0 to 4 and correspond to a category (clear, almost clear, mild, moderate and severe, respectively).

Time frame:
Baseline and all scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 13, 14, 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving >=2 Points Improvement in the IGA From Baseline at All Scheduled Time Points
percentage of participantsPlaceboPF-04965842 10mg QDPF-04965842 30mg QDPF-04965842 100mg QDPF-04965842 200mg QD
Week 11.94.26.15.59.4
Week 27.310.410.611.324.0
Week 48.011.112.825.051.9
Week 622.723.718.629.259.6
Week 814.619.423.334.059.2
Week 1217.117.223.351.257.1
Week 1313.324.112.926.337.8
Week 1421.917.910.320.025.0
Week 1614.326.911.122.231.6
SecondaryPercent Change From Baseline in the EASI Total Score at All Scheduled Time Points Except Week 12.

The EASI quantifies the severity of participants' AD based on both severity of lesion clinical signs and the percent of BSA affected. EASI is a composite scoring by the AD clinical evaluator of the degree of erythema, induration/population, excoriation, and lichenification (each scored separately) for each of 4 regions, with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD.

Time frame:
Baseline and all scheduled time points except Week 12, including Weeks 1, 2, 4, 6, 8, 13, 14, 16
Reported as:
Mean · Percent change
Percent Change From Baseline in the EASI Total Score at All Scheduled Time Points Except Week 12.
Percent changePlaceboPF-04965842 10mg QDPF-04965842 30mg QDPF-04965842 100mg QDPF-04965842 200mg QD
Week 1-12.28 ± 27.205-13.80 ± 26.526-14.85 ± 33.721-19.85 ± 30.379-41.26 ± 32.064
Week 2-23.54 ± 33.348-14.79 ± 40.474-26.29 ± 33.298-38.26 ± 39.176-63.28 ± 25.754
Week 4-24.58 ± 40.520-30.06 ± 40.852-32.81 ± 40.255-53.59 ± 35.274-78.16 ± 20.666
Week 6-39.17 ± 39.299-35.18 ± 43.498-40.16 ± 43.849-54.16 ± 53.212-83.14 ± 17.267
Week 8-36.69 ± 42.629-39.43 ± 46.270-36.83 ± 52.632-53.96 ± 53.689-84.48 ± 16.226
Week 13-29.82 ± 50.404-34.11 ± 51.089-32.97 ± 45.223-51.23 ± 45.968-66.34 ± 34.951
Week 14-35.51 ± 43.357-31.54 ± 62.829-26.25 ± 49.184-38.80 ± 49.085-57.15 ± 36.739
Week 16-35.91 ± 47.713-45.24 ± 44.576-20.80 ± 47.915-27.66 ± 54.570-55.82 ± 32.833
SecondaryPercentage of Participants Achieving >=3 Points Improvement in the Pruritus Numerical Rating Scale (NRS) From Baseline at All Scheduled Time Points

The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "worst itching due to AD over the past 24 hours" on a NRS anchored by the terms "no itching" (0) and "worst possible itching" (10). The frequency of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "frequency of itching due to AD over the past 24 hours" on a NRS anchored by the terms "never/no itching" (0) and "always/constant itching" (10).

Time frame:
Baseline and all scheduled time points, including Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 29, 43, 57, 85, 99, 113
Reported as:
Number · percentage of participants
Percentage of Participants Achieving >=3 Points Improvement in the Pruritus Numerical Rating Scale (NRS) From Baseline at All Scheduled Time Points
percentage of participantsPlaceboPF-04965842 10mg QDPF-04965842 30mg QDPF-04965842 100mg QDPF-04965842 200mg QD
Itching due to AD Day 24.06.717.014.817.0
Itching due to AD Day 38.02.214.922.228.3
Itching due to AD Day 42.02.221.322.234.6
Itching due to AD Day 52.06.729.824.136.5
Itching due to AD Day 610.08.925.524.140.4
Itching due to AD Day 711.813.325.530.242.3
Itching due to AD Day 810.013.325.043.651.0
Itching due to AD Day 98.311.126.145.550.0
Itching due to AD Day 108.211.134.043.655.8
Itching due to AD Day 1116.015.627.743.657.7
Itching due to AD Day 1222.017.838.349.160.8
Itching due to AD Day 1324.015.628.353.866.0
Itching due to AD Day 1422.419.026.748.167.3
Itching due to AD Day 1525.017.930.854.572.5
Itching due to AD Day 2932.731.137.860.074.5
Itching due to AD Day 4331.435.438.353.773.1
Itching due to AD Day 5728.831.938.354.572.0
Itching due to AD Day 8526.921.341.353.764.0
Itching due to AD Day 9933.325.933.347.541.5
Itching due to AD Day 11352.229.224.044.435.3
Frequency of itching due to AD Day 26.08.919.122.226.4
Frequency of itching due to AD Day 310.08.919.125.934.0
Frequency of itching due to AD Day 48.04.423.425.948.1
Frequency of itching due to AD Day 510.06.731.929.646.2
Frequency of itching due to AD Day 614.08.927.733.357.7
Frequency of itching due to AD Day 715.711.131.934.055.8
Frequency of itching due to AD Day 816.011.129.245.560.8
Frequency of itching due to AD Day 914.613.330.445.555.8
Frequency of itching due to AD Day 1014.313.336.245.565.4
Frequency of itching due to AD Day 1120.015.636.245.563.5
Frequency of itching due to AD Day 1218.017.838.350.960.8
Frequency of itching due to AD Day 1320.020.030.451.970.0
Frequency of itching due to AD Day 1424.523.833.348.171.4
Frequency of itching due to AD Day 1530.020.538.552.372.5
Frequency of itching due to AD Day 2928.828.940.060.074.5
Frequency of itching due to AD Day 4323.535.438.357.475.0
Frequency of itching due to AD Day 5726.929.838.354.574.0
Frequency of itching due to AD Day 8525.025.534.853.770.0
Frequency of itching due to AD Day 9930.022.237.047.539.0
Frequency of itching due to AD Day 11347.825.020.047.238.2
SecondaryPercentage of Participants Achieving >=4 Points Improvement in the Pruritus NRS From Baseline at All Scheduled Time Points

The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "worst itching due to AD over the past 24 hours" on a NRS anchored by the terms "no itching" (0) and "worst possible itching" (10). The frequency of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "frequency of itching due to AD over the past 24 hours" on a NRS anchored by the terms "never/no itching" (0) and "always/constant itching" (10).

Time frame:
Baseline and all scheduled time points, including Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 29, 43, 57, 85, 99, 113
Reported as:
Number · percentage of participants
Percentage of Participants Achieving >=4 Points Improvement in the Pruritus NRS From Baseline at All Scheduled Time Points
percentage of participantsPlaceboPF-04965842 10mg QDPF-04965842 30mg QDPF-04965842 100mg QDPF-04965842 200mg QD
Itching due to AD Day 22.02.26.510.015.2
Itching due to AD Day 30.02.213.014.021.7
Itching due to AD Day 40.00.017.414.028.9
Itching due to AD Day 52.02.219.620.026.7
Itching due to AD Day 66.12.217.424.035.6
Itching due to AD Day 78.08.919.620.437.8
Itching due to AD Day 86.14.414.929.452.3
Itching due to AD Day 92.16.720.027.551.1
Itching due to AD Day 104.26.721.729.444.4
Itching due to AD Day 118.213.319.629.444.4
Itching due to AD Day 1210.211.123.935.351.1
Itching due to AD Day 1314.36.720.038.861.4
Itching due to AD Day 1410.414.325.041.759.1
Itching due to AD Day 1515.07.931.641.970.3
Itching due to AD Day 2917.613.625.052.968.9
Itching due to AD Day 4320.022.223.950.071.7
Itching due to AD Day 5717.622.726.152.972.7
Itching due to AD Day 8525.522.733.350.063.6
Itching due to AD Day 9927.625.923.138.537.1
Itching due to AD Day 11343.520.816.734.331.0
Frequency of itching due to AD Day 22.10.07.111.518.8
Frequency of itching due to AD Day 36.42.211.913.522.9
Frequency of itching due to AD Day 42.10.019.021.236.2
Frequency of itching due to AD Day 54.34.423.825.038.3
Frequency of itching due to AD Day 610.66.726.225.044.7
Frequency of itching due to AD Day 710.44.419.030.051.1
Frequency of itching due to AD Day 88.52.223.336.554.3
Frequency of itching due to AD Day 96.76.726.836.548.9
Frequency of itching due to AD Day 106.58.931.028.851.1
Frequency of itching due to AD Day 1110.615.623.832.755.3
Frequency of itching due to AD Day 1212.813.326.234.654.3
Frequency of itching due to AD Day 1317.015.629.332.066.7
Frequency of itching due to AD Day 1419.616.730.034.766.7
Frequency of itching due to AD Day 1520.015.835.336.471.1
Frequency of itching due to AD Day 2916.315.935.051.966.0
Frequency of itching due to AD Day 4312.524.428.658.872.9
Frequency of itching due to AD Day 5716.320.533.353.873.9
Frequency of itching due to AD Day 8524.525.028.647.169.6
Frequency of itching due to AD Day 9920.718.516.739.532.4
Frequency of itching due to AD Day 11334.820.822.729.426.7
SecondaryTime to Achieving >=3 Points Improvement in NRS

The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "worst itching due to AD over the past 24 hours" on a NRS anchored by the terms "no itching" (0) and "worst possible itching" (10). The frequency of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "frequency of itching due to AD over the past 24 hours" on a NRS anchored by the terms "never/no itching" (0) and "always/constant itching" (10).

Time frame:
Baseline till Week 16
Reported as:
Median · day
Time to Achieving >=3 Points Improvement in NRS
dayPlaceboPF-04965842 10mg QDPF-04965842 30mg QDPF-04965842 100mg QDPF-04965842 200mg QD
Itching due to AD30.0 (15.0 to 56.0)43.0 (29.0 to 57.0)12.0 (8.0 to 30.0)9.0 (7.0 to 14.0)7.0 (5.0 to 11.0)
Frequency of itching due to AD29.0 (13.0 to 57.0)43.0 (29.0 to 85.0)13.0 (7.0 to 43.0)8.0 (4.0 to 10.0)4.0 (4.0 to 6.0)
SecondaryTime to Achieving >=4 Points Improvement in NRS

The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "worst itching due to AD over the past 24 hours" on a NRS anchored by the terms "no itching" (0) and "worst possible itching" (10). The frequency of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "frequency of itching due to AD over the past 24 hours" on a NRS anchored by the terms "never/no itching" (0) and "always/constant itching" (10).

Time frame:
Baseline till Week 16
Reported as:
Median · day
Time to Achieving >=4 Points Improvement in NRS
dayPlaceboPF-04965842 10mg QDPF-04965842 30mg QDPF-04965842 100mg QDPF-04965842 200mg QD
Itching due to atopic dermatitis78.0 (56.0 to NA)NA (47.0 to NA)43.0 (15.0 to 85.0)14.0 (10.0 to 29.0)10.0 (7.0 to 13.0)
Frequency of itching due to atopic dermatitis59.0 (30.0 to NA)NA (56.0 to NA)29.0 (12.0 to 98.0)14.0 (8.0 to 29.0)7.0 (5.0 to 9.0)
SecondaryPercent Change From Baseline in the Pruritus NRS From Baseline at All Scheduled Time Points

The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "worst itching due to AD over the past 24 hours" on a NRS anchored by the terms "no itching" (0) and "worst possible itching" (10). The frequency of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "frequency of itching due to AD over the past 24 hours" on a NRS anchored by the terms "never/no itching" (0) and "always/constant itching" (10).

Time frame:
Baseline and all scheduled time points, including Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 29, 43, 57, 85, 99, 113
Reported as:
Mean · percent change
Percent Change From Baseline in the Pruritus NRS From Baseline at All Scheduled Time Points
percent changePlaceboPF-04965842 10mg QDPF-04965842 30mg QDPF-04965842 100mg QDPF-04965842 200mg QD
Itching due to AD Day 20.56 ± 19.298-1.51 ± 19.857-9.39 ± 23.528-10.06 ± 25.930-6.79 ± 47.751
Itching due to AD Day 3-1.32 ± 22.6302.48 ± 21.994-8.22 ± 33.257-15.32 ± 27.874-16.72 ± 40.055
Itching due to AD Day 4-1.98 ± 22.3260.23 ± 17.314-12.18 ± 33.385-17.62 ± 25.747-25.80 ± 38.557
Itching due to AD Day 5-2.98 ± 22.385-2.37 ± 20.174-18.92 ± 31.846-20.48 ± 27.983-30.91 ± 34.215
Itching due to AD Day 6-1.52 ± 25.690-5.70 ± 23.478-16.70 ± 33.407-21.58 ± 27.842-34.02 ± 35.532
Itching due to AD Day 7-4.18 ± 30.531-4.59 ± 28.248-18.07 ± 33.640-23.02 ± 33.524-38.17 ± 35.428
Itching due to AD Day 8-0.35 ± 34.144-5.69 ± 25.576-17.87 ± 34.789-32.36 ± 30.610-43.13 ± 38.684
Itching due to AD Day 9-2.56 ± 30.688-8.61 ± 27.803-22.74 ± 33.667-31.82 ± 30.951-39.37 ± 41.055
Itching due to AD Day 10-3.32 ± 29.885-5.97 ± 29.093-22.90 ± 41.573-31.93 ± 27.094-39.60 ± 56.607
Itching due to AD Day 11-7.81 ± 30.201-5.94 ± 31.028-16.76 ± 49.412-33.13 ± 27.902-42.50 ± 51.621
Itching due to AD Day 12-11.12 ± 30.087-6.65 ± 32.617-27.84 ± 33.416-33.30 ± 34.252-46.40 ± 46.241
Itching due to AD Day 13-15.16 ± 29.759-7.43 ± 27.374-24.56 ± 30.086-35.89 ± 35.651-49.77 ± 48.426
Itching due to AD Day 14-13.61 ± 30.153-8.84 ± 29.474-26.70 ± 29.805-36.57 ± 27.552-55.45 ± 34.331
Itching due to AD Day 15-17.24 ± 30.755-7.28 ± 28.058-25.09 ± 37.815-35.41 ± 29.140-59.00 ± 39.804
Itching due to AD Day 29-19.43 ± 35.575-16.63 ± 34.554-28.41 ± 36.183-46.62 ± 40.090-68.09 ± 31.214
Itching due to AD Day 43-26.55 ± 36.418-27.15 ± 39.550-31.14 ± 39.090-49.49 ± 46.279-67.80 ± 36.372
Itching due to AD Day 57-25.54 ± 39.577-21.60 ± 44.446-29.60 ± 39.606-54.11 ± 36.374-70.13 ± 36.338
Itching due to AD Day 85-30.10 ± 42.697-22.47 ± 48.291-30.39 ± 47.772-56.51 ± 41.955-53.66 ± 109.454
Itching due to AD Day 99-19.24 ± 43.251-15.94 ± 42.332-11.46 ± 39.959-32.68 ± 34.7895.61 ± 139.223
Itching due to AD Day 113-31.99 ± 45.929-14.07 ± 47.186-14.34 ± 29.756-28.47 ± 41.02724.61 ± 190.848
Frequency of itching due to AD Day 26.72 ± 45.759-6.67 ± 19.016-10.14 ± 28.184-17.93 ± 20.967-10.52 ± 79.180
Frequency of itching due to AD Day 32.59 ± 45.5410.30 ± 24.330-3.96 ± 49.425-19.98 ± 22.910-16.46 ± 67.794
Frequency of itching due to AD Day 43.73 ± 37.683-3.25 ± 15.230-9.39 ± 39.225-20.71 ± 24.391-28.27 ± 47.925
Frequency of itching due to AD Day 5-0.70 ± 34.834-3.73 ± 23.125-17.72 ± 38.967-23.69 ± 24.954-35.45 ± 37.436
Frequency of itching due to AD Day 64.04 ± 52.799-5.76 ± 24.623-14.84 ± 38.256-26.47 ± 27.218-44.31 ± 36.476
Frequency of itching due to AD Day 7-2.25 ± 37.193-3.56 ± 25.414-17.05 ± 40.108-27.80 ± 32.466-40.19 ± 39.702
Frequency of itching due to AD Day 81.22 ± 38.544-3.90 ± 25.515-19.05 ± 36.488-35.44 ± 29.791-46.26 ± 43.491
Frequency of itching due to AD Day 91.08 ± 58.633-8.79 ± 26.589-17.58 ± 42.054-35.17 ± 29.637-44.29 ± 43.238
Frequency of itching due to AD Day 10-3.47 ± 53.518-5.41 ± 32.491-19.84 ± 47.884-33.23 ± 26.950-49.78 ± 37.349
Frequency of itching due to AD Day 11-6.24 ± 49.163-5.88 ± 32.750-18.73 ± 42.599-34.93 ± 27.181-51.62 ± 37.385
Frequency of itching due to AD Day 12-8.41 ± 49.918-5.65 ± 36.637-25.00 ± 31.695-36.55 ± 27.281-51.92 ± 40.010
Frequency of itching due to AD Day 13-13.45 ± 40.159-10.46 ± 31.103-24.73 ± 31.960-35.75 ± 32.757-53.17 ± 40.695
Frequency of itching due to AD Day 14-10.26 ± 46.126-13.86 ± 32.390-27.70 ± 30.476-38.28 ± 27.724-57.50 ± 39.073
Frequency of itching due to AD Day 15-18.78 ± 34.923-11.34 ± 28.494-26.88 ± 38.846-38.87 ± 29.184-60.99 ± 32.840
Frequency of itching due to AD Day 29-16.05 ± 39.630-17.15 ± 33.432-28.55 ± 43.421-49.94 ± 36.649-67.84 ± 29.918
Frequency of itching due to AD Day 43-24.51 ± 30.798-32.19 ± 37.806-26.48 ± 46.793-53.95 ± 41.772-69.24 ± 38.370
Frequency of itching due to AD Day 57-24.94 ± 35.662-23.28 ± 44.257-27.91 ± 39.142-55.39 ± 35.447-73.50 ± 30.583
Frequency of itching due to AD Day 85-29.81 ± 44.035-25.76 ± 43.273-32.28 ± 38.817-54.51 ± 43.354-54.54 ± 120.723
Frequency of itching due to AD Day 99-17.46 ± 43.552-20.21 ± 36.947-3.36 ± 52.153-13.57 ± 123.8002.12 ± 144.572
Frequency of itching due to AD Day 113-28.95 ± 46.896-16.22 ± 38.055-5.65 ± 51.132-12.62 ± 113.42327.77 ± 203.937
SecondaryChange From Baseline in Pruritus NRS Score at All Scheduled Time Points

The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "worst itching due to AD over the past 24 hours" on a NRS anchored by the terms "no itching" (0) and "worst possible itching" (10). The frequency of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants were asked to assess their "frequency of itching due to AD over the past 24 hours" on a NRS anchored by the terms "never/no itching" (0) and "always/constant itching" (10).

Time frame:
Baseline and all scheduled time points, including Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 29, 43, 57, 85, 99, 113
Reported as:
Mean · units on a scale
Change From Baseline in Pruritus NRS Score at All Scheduled Time Points
units on a scalePlaceboPF-04965842 10mg QDPF-04965842 30mg QDPF-04965842 100mg QDPF-04965842 200mg QD
Itching due to AD Day 2-0.08 ± 1.307-0.20 ± 1.217-0.83 ± 1.672-0.85 ± 1.607-1.00 ± 2.433
Itching due to AD Day 3-0.22 ± 1.4180.02 ± 1.357-0.85 ± 2.095-1.21 ± 1.702-1.48 ± 2.493
Itching due to AD Day 4-0.22 ± 1.389-0.09 ± 1.117-1.09 ± 2.263-1.26 ± 1.862-2.12 ± 2.590
Itching due to AD Day 5-0.32 ± 1.406-0.27 ± 1.264-1.55 ± 2.348-1.58 ± 1.865-2.35 ± 2.583
Itching due to AD Day 6-0.28 ± 1.727-0.55 ± 1.405-1.47 ± 2.492-1.49 ± 2.317-2.53 ± 2.648
Itching due to AD Day 7-0.53 ± 2.023-0.52 ± 1.745-1.51 ± 2.422-1.75 ± 2.159-2.77 ± 2.795
Itching due to AD Day 8-0.30 ± 2.215-0.56 ± 1.560-1.65 ± 2.514-2.39 ± 2.294-3.22 ± 3.039
Itching due to AD Day 9-0.38 ± 2.080-0.75 ± 1.844-1.95 ± 2.527-2.40 ± 2.154-3.18 ± 2.988
Itching due to AD Day 10-0.43 ± 1.947-0.61 ± 1.967-2.09 ± 2.698-2.21 ± 2.412-3.38 ± 2.975
Itching due to AD Day 11-0.73 ± 1.955-0.61 ± 2.148-1.72 ± 2.462-2.33 ± 2.415-3.40 ± 3.071
Itching due to AD Day 12-0.92 ± 1.988-0.73 ± 2.245-2.28 ± 2.271-2.46 ± 2.578-3.63 ± 3.154
Itching due to AD Day 13-1.21 ± 1.989-0.68 ± 1.801-1.98 ± 2.268-2.84 ± 2.164-3.88 ± 3.085
Itching due to AD Day 14-1.11 ± 2.003-0.78 ± 2.104-2.10 ± 2.211-2.53 ± 2.567-4.06 ± 2.793
Itching due to AD Day 15-1.39 ± 2.034-0.69 ± 1.937-2.06 ± 2.508-2.79 ± 2.290-4.37 ± 2.696
Itching due to AD Day 29-1.63 ± 2.453-1.34 ± 2.383-2.17 ± 2.519-3.58 ± 3.322-5.00 ± 2.880
Itching due to AD Day 43-1.93 ± 2.325-2.24 ± 2.929-2.50 ± 2.562-3.77 ± 3.778-5.02 ± 3.172
Itching due to AD Day 57-1.84 ± 2.594-1.97 ± 3.398-2.55 ± 2.943-4.00 ± 3.336-5.26 ± 3.130
Itching due to AD Day 85-2.26 ± 3.081-2.13 ± 3.711-2.68 ± 2.749-4.21 ± 3.529-4.84 ± 3.785
Itching due to AD Day 99-1.57 ± 3.025-1.48 ± 2.992-1.37 ± 2.452-2.28 ± 2.900-1.90 ± 3.767
Itching due to AD Day 113-2.43 ± 3.259-1.38 ± 3.201-1.32 ± 2.410-2.03 ± 3.185-1.50 ± 3.736
Frequency of itching due to AD Day 2-0.06 ± 1.754-0.44 ± 1.198-0.94 ± 1.737-1.35 ± 1.556-1.60 ± 2.345
Frequency of itching due to AD Day 3-0.38 ± 1.894-0.16 ± 1.461-0.79 ± 2.331-1.49 ± 1.694-1.92 ± 2.300
Frequency of itching due to AD Day 4-0.20 ± 1.738-0.32 ± 1.073-1.02 ± 2.162-1.40 ± 2.069-2.47 ± 2.533
Frequency of itching due to AD Day 5-0.42 ± 1.727-0.43 ± 1.516-1.49 ± 2.349-1.75 ± 1.828-2.73 ± 2.515
Frequency of itching due to AD Day 6-0.40 ± 2.250-0.55 ± 1.606-1.40 ± 2.402-1.77 ± 2.326-3.24 ± 2.446
Frequency of itching due to AD Day 7-0.63 ± 2.181-0.43 ± 1.676-1.53 ± 2.466-2.04 ± 2.214-3.15 ± 2.739
Frequency of itching due to AD Day 8-0.42 ± 2.205-0.40 ± 1.679-1.74 ± 2.542-2.59 ± 2.278-3.69 ± 2.808
Frequency of itching due to AD Day 9-0.54 ± 2.240-0.75 ± 2.036-1.74 ± 2.567-2.62 ± 2.268-3.54 ± 3.018
Frequency of itching due to AD Day 10-0.80 ± 2.198-0.64 ± 2.200-1.84 ± 2.760-2.33 ± 2.565-3.68 ± 2.591
Frequency of itching due to AD Day 11-0.96 ± 2.336-0.68 ± 2.380-1.79 ± 2.541-2.46 ± 2.540-3.74 ± 2.633
Frequency of itching due to AD Day 12-1.06 ± 2.322-0.66 ± 2.411-2.00 ± 2.182-2.54 ± 2.509-3.84 ± 2.932
Frequency of itching due to AD Day 13-1.33 ± 2.337-0.91 ± 2.133-1.90 ± 2.195-2.78 ± 2.275-4.08 ± 2.952
Frequency of itching due to AD Day 14-1.17 ± 2.417-1.10 ± 2.417-2.00 ± 2.225-2.63 ± 2.620-4.28 ± 2.841
Frequency of itching due to AD Day 15-1.50 ± 2.322-0.97 ± 2.135-2.17 ± 2.407-3.02 ± 2.464-4.50 ± 2.648
Frequency of itching due to AD Day 29-1.46 ± 2.518-1.34 ± 2.425-2.22 ± 2.761-3.77 ± 3.317-5.06 ± 2.817
Frequency of itching due to AD Day 43-1.70 ± 1.990-2.51 ± 3.061-2.28 ± 2.953-4.02 ± 3.796-5.30 ± 2.957
Frequency of itching due to AD Day 57-1.74 ± 2.298-2.00 ± 3.499-2.45 ± 2.943-4.02 ± 3.467-5.59 ± 3.037
Frequency of itching due to AD Day 85-2.23 ± 3.209-2.33 ± 3.575-2.61 ± 2.692-4.09 ± 3.663-5.14 ± 3.645
Frequency of itching due to AD Day 99-1.30 ± 2.781-1.56 ± 2.736-0.93 ± 2.526-2.03 ± 3.378-2.15 ± 3.909
Frequency of itching due to AD Day 113-2.00 ± 2.970-1.42 ± 3.035-1.04 ± 2.557-1.81 ± 3.188-1.50 ± 3.816
SecondaryPercentage of Participants Achieving a >=50% Improvement in the EASI Total Score (EASI50) at All Scheduled Time Points

The EASI quantifies the severity of participants' AD based on both severity of lesion clinical signs and the percent of BSA affected. EASI is a composite scoring by the AD clinical evaluator of the degree of erythema, induration/population, excoriation, and lichenification (each scored separately) for each of 4 regions, with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD.

Time frame:
All scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 13, 14, 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a >=50% Improvement in the EASI Total Score (EASI50) at All Scheduled Time Points
percentage of participantsPlaceboPF-04965842 10mg QDPF-04965842 30mg QDPF-04965842 100mg QDPF-04965842 200mg QD
Week 19.38.314.012.740.7
Week 227.316.324.036.465.4
Week 427.330.636.058.285.2
Week 636.430.640.060.090.7
Week 830.936.740.060.090.6
Week 1226.926.133.355.679.2
Week 1343.341.445.255.375.6
Week 1437.542.937.950.065.9
Week 1642.942.333.341.768.4
SecondaryPercentage of Participants Achieving a >=75% Improvement in the EASI Total Score (EASI75) at All Scheduled Time Points

The EASI quantifies the severity of participants' AD based on both severity of lesion clinical signs and the percent of BSA affected. EASI is a composite scoring by the AD clinical evaluator of the degree of erythema, induration/population, excoriation, and lichenification (each scored separately) for each of 4 regions, with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD.

Time frame:
All scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 13, 14, 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a >=75% Improvement in the EASI Total Score (EASI75) at All Scheduled Time Points
percentage of participantsPlaceboPF-04965842 10mg QDPF-04965842 30mg QDPF-04965842 100mg QDPF-04965842 200mg QD
Week 13.72.16.03.616.7
Week 25.512.26.012.736.5
Week 410.918.420.027.357.4
Week 616.418.418.038.268.5
Week 820.022.422.040.073.6
Week 1215.417.413.340.764.6
Week 1326.727.612.936.855.6
Week 1431.325.06.935.045.5
Week 1632.138.53.725.036.8
SecondaryPercentage of Participants Achieving a >=90% Improvement in the EASI Total Score (EASI90) at All Scheduled Time Points

The EASI quantifies the severity of participants' AD based on both severity of lesion clinical signs and the percent of BSA affected. EASI is a composite scoring by the AD clinical evaluator of the degree of erythema, induration/population, excoriation, and lichenification (each scored separately) for each of 4 regions, with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD.

Time frame:
All scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 13, 14, 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a >=90% Improvement in the EASI Total Score (EASI90) at All Scheduled Time Points
percentage of participantsPlaceboPF-04965842 10mg QDPF-04965842 30mg QDPF-04965842 100mg QDPF-04965842 200mg QD
Week 10.02.14.00.07.4
Week 20.06.14.05.519.2
Week 41.88.28.010.938.9
Week 67.314.314.016.444.4
Week 85.512.28.023.643.4
Week 129.610.90.025.952.1
Week 1310.013.83.223.731.1
Week 1415.614.30.017.518.2
Week 1614.323.13.78.310.5
SecondaryChange From Baseline in Affected BSA at All Scheduled Time Points

BSA Efficacy is derived from the sum of the BSA in handprints across 4 body regions assessed as part of the EASI assessment. Handprint refers to that of each individual participant for their own measurement. The BSA Efficacy ranges from 0 to 100%, with higher values representing greater severity of AD. Since the scalp, palms, and soles are excluded from the BSA (Efficacy) assessment, the maximum possible value is less than 100%.

Time frame:
Baseline and all scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 13, 14, 16
Reported as:
Mean · percentage of BSA
Change From Baseline in Affected BSA at All Scheduled Time Points
percentage of BSAPlaceboPF-04965842 10mg QDPF-04965842 30mg QDPF-04965842 100mg QDPF-04965842 200mg QD
Week 1-0.06 ± 6.699-3.76 ± 13.940-2.45 ± 7.017-4.63 ± 12.144-10.86 ± 15.690
Week 2-5.43 ± 10.030-4.84 ± 16.179-6.51 ± 10.485-10.80 ± 16.432-21.30 ± 19.285
Week 4-6.34 ± 16.138-8.93 ± 15.960-9.59 ± 14.845-17.77 ± 19.956-28.55 ± 20.447
Week 6-10.79 ± 16.413-11.80 ± 22.324-10.71 ± 15.007-18.80 ± 23.387-30.51 ± 20.853
Week 8-9.71 ± 17.837-12.98 ± 25.552-10.79 ± 19.259-19.41 ± 23.596-29.98 ± 20.864
Week 12-13.82 ± 22.348-11.59 ± 27.112-9.37 ± 18.783-22.21 ± 22.199-27.72 ± 18.361
Week 13-7.90 ± 18.233-11.07 ± 25.457-7.79 ± 17.469-17.88 ± 20.905-22.61 ± 22.390
Week 14-8.97 ± 16.223-10.46 ± 26.130-6.33 ± 17.404-12.75 ± 22.492-16.35 ± 18.931
Week 16-8.09 ± 15.797-14.64 ± 20.948-3.52 ± 20.967-5.55 ± 21.079-17.88 ± 17.059
SecondaryChange From Baseline in Scoring Atopic Dermatitis (SCORAD) at All Scheduled Time Points

SCORAD is a validated scoring index for AD, which combines extent (0-100), severity (0-18), and subjective symptoms (0-20) based on pruritus and sleep loss, each scored (0-10). Extent, denoted as A, is measured by BSA affected by AD as a percentage of the whole BSA. The score for each body region is added up to determine A (maximum of 100%). Severity, denoted as B, consists of the severity of several signs. Each is assessed as none(0), mild(1), moderate(2) or severe(3). The severity scores are added together to give B (maximum of 18). Subjective symptoms, denoted as C, are each scored by the subject or caregiver using a numeric rating scale (NRS) where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness). These scores are added to give 'C' (maximum of 20). The SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103). Higher values of SCORAD represent worse outcome.

Time frame:
Baseline and all scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 13, 14, 16
Reported as:
Mean · units on a scale
Change From Baseline in Scoring Atopic Dermatitis (SCORAD) at All Scheduled Time Points
units on a scalePlaceboPF-04965842 10mg QDPF-04965842 30mg QDPF-04965842 100mg QDPF-04965842 200mg QD
Week 1-7.910 ± 12.4625-5.000 ± 13.3310-8.388 ± 14.6316-12.024 ± 12.4053-21.326 ± 15.8867
Week 2-10.905 ± 15.4157-8.795 ± 16.3883-13.266 ± 14.5268-20.286 ± 15.2402-32.152 ± 14.4354
Week 4-14.555 ± 16.6414-14.116 ± 19.1643-15.496 ± 16.4795-28.058 ± 16.6775-39.567 ± 14.7328
Week 6-19.527 ± 16.7869-16.667 ± 21.8577-19.930 ± 17.5966-29.729 ± 21.6156-41.458 ± 14.3943
Week 8-19.052 ± 18.5735-18.853 ± 21.7947-19.534 ± 18.7098-30.148 ± 20.7887-42.604 ± 13.9771
Week 12-18.647 ± 20.0191-17.986 ± 23.1948-21.211 ± 17.6774-33.145 ± 21.4221-41.384 ± 15.4359
Week 13-16.603 ± 21.3850-16.895 ± 22.1132-15.023 ± 16.1573-24.261 ± 19.4912-29.884 ± 19.1501
Week 14-17.987 ± 22.0893-15.842 ± 19.5000-12.768 ± 13.6914-20.211 ± 20.2920-21.292 ± 17.7775
Week 16-19.408 ± 22.1744-18.925 ± 21.5459-12.716 ± 15.9390-17.753 ± 19.1842-21.024 ± 18.1576
SecondaryPercent Change From Baseline in SCORAD at All Scheduled Time Points

SCORAD is a validated scoring index for AD, which combines extent (0-100), severity (0-18), and subjective symptoms (0-20) based on pruritus and sleep loss, each scored (0-10). Extent, denoted as A, is measured by BSA affected by AD as a percentage of the whole BSA. The score for each body region is added up to determine A (maximum of 100%). Severity, denoted as B, consists of the severity of several signs. Each is assessed as none(0), mild(1), moderate(2) or severe(3). The severity scores are added together to give B (maximum of 18). Subjective symptoms, denoted as C, are each scored by the subject or caregiver using a numeric rating scale (NRS) where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness). These scores are added to give 'C' (maximum of 20). The SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103). Higher values of SCORAD represent worse outcome.

Time frame:
Baseline and all scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 13, 14, 16
Reported as:
Mean · percent change
Percent Change From Baseline in SCORAD at All Scheduled Time Points
percent changePlaceboPF-04965842 10mg QDPF-04965842 30mg QDPF-04965842 100mg QDPF-04965842 200mg QD
Week 1-11.547 ± 19.7128-7.287 ± 20.6403-13.068 ± 21.0746-19.185 ± 20.0094-34.660 ± 25.0837
Week 2-16.488 ± 23.0011-12.980 ± 25.5198-20.613 ± 21.0283-31.025 ± 23.9881-51.384 ± 21.3581
Week 4-22.476 ± 26.5163-20.751 ± 29.0846-24.866 ± 25.3755-43.846 ± 26.2001-63.970 ± 21.6701
Week 6-30.789 ± 27.9424-25.851 ± 34.2950-31.276 ± 29.6517-45.270 ± 34.3893-66.971 ± 22.4343
Week 8-29.624 ± 30.5625-28.599 ± 33.1460-30.480 ± 29.4742-46.187 ± 32.7984-69.736 ± 21.4403
Week 12-29.379 ± 31.9081-27.607 ± 36.5015-32.535 ± 25.2711-51.624 ± 33.0106-68.537 ± 24.2392
Week 13-26.794 ± 34.3384-26.905 ± 34.1879-24.232 ± 26.2461-38.193 ± 32.3458-48.428 ± 30.1133
Week 14-29.393 ± 36.6642-25.511 ± 31.1985-20.072 ± 21.7399-31.521 ± 34.1268-36.519 ± 28.5404
Week 16-31.972 ± 36.5058-30.135 ± 34.2361-19.794 ± 25.0550-29.130 ± 33.1868-34.995 ± 27.4996
SecondaryPercentage of Participants Achieving a >=50% Improvement in SCORAD (SCORAD50) From Baseline at All Scheduled Time Points

SCORAD is a validated scoring index for AD, which combines extent (0-100), severity (0-18), and subjective symptoms (0-20) based on pruritus and sleep loss, each scored (0-10). Extent, denoted as A, is measured by BSA affected by AD as a percentage of the whole BSA. The score for each body region is added up to determine A (maximum of 100%). Severity, denoted as B, consists of the severity of several signs. Each is assessed as none(0), mild(1), moderate(2) or severe(3). The severity scores are added together to give B (maximum of 18). Subjective symptoms, denoted as C, are each scored by the subject or caregiver using a numeric rating scale (NRS) where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness). These scores are added to give 'C' (maximum of 20). The SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103). Higher values of SCORAD represent worse outcome.

Time frame:
Baseline and all scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 13, 14, 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a >=50% Improvement in SCORAD (SCORAD50) From Baseline at All Scheduled Time Points
percentage of participantsPlaceboPF-04965842 10mg QDPF-04965842 30mg QDPF-04965842 100mg QDPF-04965842 200mg QD
Week 13.72.16.07.329.6
Week 25.510.210.018.255.8
Week 420.012.216.043.675.9
Week 621.816.326.045.574.1
Week 823.622.430.043.673.6
Week 1219.213.015.650.072.9
Week 1326.720.716.134.248.9
Week 1431.317.93.432.536.4
Week 1639.330.814.825.034.2
SecondaryPercentage of Participants Achieving a >=75% Improvement in SCORAD (SCORAD75) From Baseline at All Scheduled Time Points

SCORAD is a validated scoring index for AD, which combines extent (0-100), severity (0-18), and subjective symptoms (0-20) based on pruritus and sleep loss, each scored (0-10). Extent, denoted as A, is measured by BSA affected by AD as a percentage of the whole BSA. The score for each body region is added up to determine A (maximum of 100%). Severity, denoted as B, consists of the severity of several signs. Each is assessed as none(0), mild(1), moderate(2) or severe(3). The severity scores are added together to give B (maximum of 18). Subjective symptoms, denoted as C, are each scored by the subject or caregiver using a numeric rating scale (NRS) where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness). These scores are added to give 'C' (maximum of 20). The SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103). Higher values of SCORAD represent worse outcome.

Time frame:
Baseline and all scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 13, 14, 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a >=75% Improvement in SCORAD (SCORAD75) From Baseline at All Scheduled Time Points
percentage of participantsPlaceboPF-04965842 10mg QDPF-04965842 30mg QDPF-04965842 100mg QDPF-04965842 200mg QD
Week 10.02.12.01.83.7
Week 20.02.02.03.611.5
Week 41.84.14.014.527.8
Week 65.512.24.020.037.0
Week 83.66.12.016.435.8
Week 123.810.90.018.537.5
Week 1313.310.30.018.415.6
Week 1415.67.10.012.511.4
Week 1614.311.50.011.12.6
SecondaryNumber of Participants With Treatment-emergent Adverse Events (AEs)

An AE was any untoward medical occurrence in a subject administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Treatment-emergent AEs were events that occurred between the first dose of study drug and the subject's last visit (Week 16) that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Baseline till Week 16
Reported as:
Number · participants
Number of Participants With Treatment-emergent Adverse Events (AEs)
participantsPlaceboPF-04965842 10mg QDPF-04965842 30mg QDPF-04965842 100mg QDPF-04965842 200mg QD
Number of Participants With Treatment-emergent Adverse Events (AEs)3234344341
SecondaryNumber of Participants With Specific Clinical Laboratory Abnormalities (Anemia, Neutropenia, Thrombocytopenia, Lymphopenia, Lipid Profile, Liver Function Tests (LFTs)
Time frame:
Baseline up to Week 16
Reported as:
Number · participants
Number of Participants With Specific Clinical Laboratory Abnormalities (Anemia, Neutropenia, Thrombocytopenia, Lymphopenia, Lipid Profile, Liver Function Tests (LFTs)
participantsPlaceboPF-04965842 10mg QDPF-04965842 30mg QDPF-04965842 100mg QDPF-04965842 200mg QD
AEs of anemia00000
AEs of neutropenia00001
AEs of thrombocytopenia00001
AEs of lymphopenia00000
AEs of lipid profile00000
AEs of liver function tests00000
SecondaryPercentage of Participants With Patient Global Assessment (PtGA) of AD of Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at All Scheduled Time Points

The PtGA asked the participant to evaluate the overall cutaneous disease at that point in time on a single-item, 5-point scale. The same category labels used in the Physician's Global Assessment was used for the PtGA, ie, "severe (4)", "moderate (3)", "mild (2)","almost clear (1)", and "clear (0)". The PtGA was completed as per schedule of activities.

Time frame:
Baseline and all scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 14, 16
Reported as:
Number · percentage of participants
Percentage of Participants With Patient Global Assessment (PtGA) of AD of Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at All Scheduled Time Points
percentage of participantsPlaceboPF-04965842 10mg QDPF-04965842 30mg QDPF-04965842 100mg QDPF-04965842 200mg QD
Week 10.02.14.11.916.7
Week 25.60.06.116.732.7
Week 43.86.18.222.254.7
Week 63.810.28.222.251.9
Week 81.96.16.124.156.6
Week 127.412.50.025.951.9
Week 143.210.30.015.815.6
Week 1611.17.70.011.810.5
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI) Total Score at All Scheduled Time Points

The DLQI is a general dermatology questionnaire that consists of 10 items that assess participant health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). It has been extensively used in clinical trials for AD. The DLQI is a psychometrically valid and reliable instrument that has been translated into several languages, and the DLQI total scores have been shown to be responsive to change. The minimally important difference for the DLQI has been estimated as a 2-5 point change from baseline. Each item is scored as "very much (3)", "a lot (2)", "a little (1)" and "not at all (0)". The score can range from 0 to 30. The higher values represent the worse dermatology life quality.

Time frame:
Baseline and all scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 14, 16
Reported as:
Mean · units on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at All Scheduled Time Points
units on a scalePlaceboPF-04965842 10mg QDPF-04965842 30mg QDPF-04965842 100mg QDPF-04965842 200mg QD
Week 1-1.4 ± 6.04-1.4 ± 5.66-3.4 ± 6.28-5.1 ± 5.40-6.3 ± 5.55
Week 2-2.3 ± 5.42-1.9 ± 6.58-5.0 ± 5.55-7.5 ± 6.39-8.6 ± 6.46
Week 4-2.6 ± 6.77-3.7 ± 7.33-4.7 ± 5.62-8.2 ± 7.48-9.7 ± 6.82
Week 6-4.2 ± 6.01-4.6 ± 7.30-4.1 ± 7.75-9.1 ± 6.75-10.2 ± 6.72
Week 8-3.7 ± 7.67-5.6 ± 8.44-4.8 ± 8.52-9.2 ± 7.95-9.8 ± 7.10
Week 12-4.6 ± 8.49-4.5 ± 8.90-5.2 ± 7.30-9.8 ± 8.18-9.5 ± 7.28
Week 14-3.1 ± 8.24-3.9 ± 7.62-3.6 ± 6.60-6.2 ± 7.87-4.4 ± 8.78
Week 16-4.5 ± 7.95-4.5 ± 7.14-3.5 ± 7.17-4.6 ± 7.62-3.6 ± 7.39
SecondaryChange From Baseline in Patient Oriented Eczema Measure (POEM) at All Scheduled Time Points

The POEM is a 7-item patient reported outcome (PRO) measure used to assess the impact of AD over the past week. Each item is scored as "no days (0)", "1-2 days (1)", "3-4 days (2)", "5-6 days (3)" and "every day (4)". The score ranges from 0 to 28. The higher values represent more severe AD.

Time frame:
Baseline and all scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 14, 16
Reported as:
Mean · units on a scale
Change From Baseline in Patient Oriented Eczema Measure (POEM) at All Scheduled Time Points
units on a scalePlaceboPF-04965842 10mg QDPF-04965842 30mg QDPF-04965842 100mg QDPF-04965842 200mg QD
Week 1-1.1 ± 3.59-0.6 ± 4.17-2.1 ± 5.83-3.9 ± 4.67-9.2 ± 5.77
Week 2-2.2 ± 4.20-1.9 ± 6.13-4.1 ± 6.04-7.2 ± 6.79-11.9 ± 5.95
Week 4-2.2 ± 6.05-3.6 ± 6.35-4.3 ± 5.69-8.7 ± 8.30-14.6 ± 6.20
Week 6-3.5 ± 5.24-4.3 ± 7.63-3.9 ± 7.43-10.4 ± 8.17-15.0 ± 5.92
Week 8-2.3 ± 5.91-4.3 ± 8.94-5.4 ± 8.05-10.6 ± 8.47-15.2 ± 6.15
Week 12-3.8 ± 8.21-4.7 ± 8.83-5.3 ± 7.60-11.4 ± 8.08-15.1 ± 6.99
Week 14-2.2 ± 6.45-3.9 ± 8.04-2.7 ± 6.05-6.3 ± 7.12-6.2 ± 6.97
Week 16-3.0 ± 7.76-3.0 ± 7.67-2.2 ± 6.80-4.3 ± 6.20-5.9 ± 5.93
SecondaryChange From Baseline in the Hospital and Anxiety Depression Scale (HADS) at All Scheduled Time Points

The HADS is a 14-item PRO measure used to detect states of anxiety and depression over the past week. The HADS was completed as per schedule of activities. Seven of the items relate to anxiety and seven relate to depression. Each item is scored from 0 to 3 which means a person can score between 0 to 21 for either anxiety or depression. Higher values represent worse outcome.

Time frame:
Baseline and all scheduled time points, including Weeks 1, 2, 4, 6, 8, 12, 14, 16
Reported as:
Mean · units on a scale
Change From Baseline in the Hospital and Anxiety Depression Scale (HADS) at All Scheduled Time Points
units on a scalePlaceboPF-04965842 10mg QDPF-04965842 30mg QDPF-04965842 100mg QDPF-04965842 200mg QD
Depression score Week 1-0.5 ± 2.710.0 ± 2.38-0.6 ± 2.49-0.9 ± 2.94-1.0 ± 2.16
Depression score Week 2-0.5 ± 2.780.4 ± 2.99-1.1 ± 1.85-1.2 ± 2.93-1.8 ± 2.66
Depression score Week 4-0.5 ± 3.00-0.4 ± 3.26-0.8 ± 2.05-1.5 ± 3.35-2.1 ± 3.30
Depression score Week 8-0.7 ± 3.31-1.3 ± 3.76-0.9 ± 2.84-2.1 ± 3.35-1.7 ± 3.08
Depression score Week 12-0.9 ± 3.96-0.9 ± 3.65-0.5 ± 2.83-2.4 ± 3.74-1.8 ± 3.90
Depression score Week 140.1 ± 3.41-1.2 ± 3.50-0.9 ± 1.53-1.7 ± 4.31-0.1 ± 4.18
Depression score Week 16-0.7 ± 3.18-1.1 ± 3.59-1.0 ± 1.85-1.4 ± 3.93-0.1 ± 3.57
Anxiety score Week 1-1.0 ± 2.660.2 ± 2.41-0.2 ± 2.49-1.1 ± 2.26-1.2 ± 2.71
Anxiety score Week 2-1.5 ± 2.87-0.4 ± 2.56-0.9 ± 2.88-1.7 ± 2.81-2.4 ± 3.15
Anxiety score Week 4-1.6 ± 3.18-1.0 ± 2.80-0.7 ± 2.69-1.7 ± 2.95-2.4 ± 4.04
Anxiety score Week 8-1.7 ± 2.33-1.6 ± 2.67-1.4 ± 3.21-2.7 ± 3.44-2.5 ± 3.31
Anxiety score Week 12-2.6 ± 3.01-1.5 ± 2.85-1.0 ± 3.43-2.8 ± 3.71-2.5 ± 3.51
Anxiety score Week 14-2.3 ± 3.43-1.5 ± 3.17-1.4 ± 2.96-2.0 ± 3.49-1.5 ± 3.93
Anxiety score Week 16-2.9 ± 3.75-2.2 ± 3.38-0.7 ± 3.27-1.4 ± 3.85-1.5 ± 3.10

Adverse events

Collected over Baseline up to Week 16. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/56 (0%)2/56 (3.6%)17/56 (30.4%)
PF-04965842 10mg QD0/49 (0%)2/49 (4.1%)18/49 (36.7%)
PF-04965842 30mg QD0/51 (0%)0/51 (0%)25/51 (49%)
PF-04965842 100mg QD0/56 (0%)3/56 (5.4%)25/56 (44.6%)
PF-04965842 200mg QD0/55 (0%)2/55 (3.6%)27/55 (49.1%)
Most frequent serious events
Most frequent serious events
EventPlaceboPF-04965842 10mg QDPF-04965842 30mg QDPF-04965842 100mg QDPF-04965842 200mg QD
Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/561/490/510/560/55
AsthmaRespiratory, thoracic and mediastinal disorders0/561/490/511/560/55
PneumoniaInfections and infestations0/560/490/510/561/55
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/560/490/510/561/55
Eczema herpeticumInfections and infestations0/560/490/511/560/55
Dermatitis atopicSkin and subcutaneous tissue disorders1/560/490/511/560/55
Dermatitis exfoliativeSkin and subcutaneous tissue disorders1/560/490/510/560/55
Most frequent other events
Most frequent other events
EventPlaceboPF-04965842 10mg QDPF-04965842 30mg QDPF-04965842 100mg QDPF-04965842 200mg QD
Viral upper respiratory tract infectionInfections and infestations5/565/496/5110/567/55
Dermatitis atopicSkin and subcutaneous tissue disorders6/568/499/517/567/55
NauseaGastrointestinal disorders1/563/493/511/568/55
Upper respiratory tract infectionInfections and infestations5/563/495/513/565/55
HeadacheNervous system disorders2/562/495/515/564/55
DiarrhoeaGastrointestinal disorders1/563/491/511/565/55
DizzinessNervous system disorders0/560/491/510/563/55
Dermatitis contactSkin and subcutaneous tissue disorders0/560/490/513/560/55

Baseline characteristics

The Full Analysis Set (FAS) was defined as all randomized participants who received at least 1 dose of study medication.

Age, Continuous
Age, Continuous(years)PlaceboPF-04965842 10mg QDPF-04965842 30mg QDPF-04965842 100mg QDPF-04965842 200mg QDTotal
Mean42.6 ± 15.144.3 ± 15.937.6 ± 15.941.1 ± 15.638.7 ± 17.640.8 ± 16.1
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboPF-04965842 10mg QDPF-04965842 30mg QDPF-04965842 100mg QDPF-04965842 200mg QDTotal
Female3528292527144
Male2121223128123
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboPF-04965842 10mg QDPF-04965842 30mg QDPF-04965842 100mg QDPF-04965842 200mg QDTotal
White4038394037194
Black105471339
Asian4558527
Other213107
08

Study locations

64 sites
  • Clinical Research Center of Alabama
    Birmingham, Alabama 35209, United States
  • California Dermatology & Clinical Research Institute
    Encinitas, California 92024, United States
  • Huntington Medical Foundation
    Pasadena, California 91105, United States
  • Peninsula Research Associates, Inc.
    Rolling Hills Estates, California 90274, United States
  • Emil A. Tanghetti MD dba Center for Dermatology and Laser Surgery
    Sacramento, California 95819, United States
  • TCR Medical Corporation
    San Diego, California 92123, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • University of Connecticut Health Center (UConn Health)
    Farmington, Connecticut 06032, United States
  • Olympian Clinical Research
    Clearwater, Florida 33756, United States
  • North Florida Dermatology Associates, PA
    Jacksonville, Florida 32204, United States
  • Park Avenue Dermatology Administration Annex
    Orange Park, Florida 32073, United States
  • Park Avenue Dermatology
    Orange Park, Florida 32073, United States
  • Leavitt Medical Associates of Florida d/b/a Ameriderm Research
    Ormond Beach, Florida 32174, United States
  • Forward Clinical Trials, Inc.
    Tampa, Florida 33624, United States
  • MedaPhase, Inc.
    Newnan, Georgia 30263, United States
  • Dundee Dermatology
    West Dundee, Illinois 60118, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46256, United States
  • Dawes Fretzin Dermatology Group, LLC
    Indianapolis, Indiana 46256, United States
  • The Indiana Clinical Trials Center
    Plainfield, Indiana 46168, United States
  • DS Research
    Louisville, Kentucky 40241, United States
  • Shondra L Smith, MD Dermatology & Advanced Aesthetics
    Lake Charles, Louisiana 70605, United States
  • Somerset Skin Centre
    Troy, Michigan 48084, United States
  • MediSearch Clinical Trials
    Saint Joseph, Missouri 64506, United States
  • Clinical Research Consortium
    Las Vegas, Nevada 89119, United States
  • Psoriasis Treatment Center of Central New Jersey
    East Windsor, New Jersey 08520, United States
  • The Dermatology Group, P.C
    Verona, New Jersey 07044, United States
  • Forest Hills Dermatology Group
    Forest Hills, New York 11375, United States
  • Sadick Research Group
    New York, New York 10075, United States
  • Vital Prospects Clinical Research Institute, P.C
    Tulsa, Oklahoma 74136, United States
  • DermDox Centers for Dermatology
    Hazleton, Pennsylvania 18201, United States
  • UPMC Department of Dermatology
    Pittsburgh, Pennsylvania 15213, United States
  • Clinical Partners, LLC
    Johnston, Rhode Island 02919, United States
  • Health Concepts
    Rapid City, South Dakota 57702, United States
  • Bellaire Dermatology Associates
    Bellaire, Texas 77401, United States
  • Texas Dermatology and Laser Specialists
    San Antonio, Texas 78218, United States
  • Virginia Clinical Research,Inc
    Norfolk, Virginia 23502, United States
  • West End Dermatology Associates
    Richmond, Virginia 23233, United States
  • Woden Dermatology
    Phillip, Australian Capital Territory 2606, Australia
  • Australian Clinical Research Network
    Sydney, New South Wales 2035, Australia
  • The Skin Centre
    Benowa, Queensland 4217, Australia
  • Veracity Clinical Research
    Woolloongabba, Queensland 4102, Australia
  • Sinclair Dermatology
    East Melbourne, Victoria 3002, Australia
  • Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • Fremantle Dermatology
    Fremantle, Western Australia 6160, Australia
  • North Eastern Health Specialists
    Hectorville, South Australia, 5073, Australia
  • University of British Columbia
    Vancouver, British Columbia V5Z 4E8, Canada
  • Wiseman Dermatology Research Inc.
    Winnipeg, Manitoba R3M 3Z4, Canada
  • Lynderm Research Inc.
    Markham, Ontario L3P 1X2, Canada
  • Research by ICLS
    Oakville, Ontario L6J 7W5, Canada
  • Skin Centre for Dermatology
    Peterborough, Ontario K9J 5K2, Canada
  • The Centre for Dermatology
    Richmond Hill, Ontario L4B IA5, Canada
  • K. Papp Clinical Research
    Waterloo, Ontario N2J 1C4, Canada
  • Windsor Clinical Research Inc
    Windsor, Ontario N8W 5L7, Canada
  • Innovaderm Research Inc.
    Montreal, Quebec H2K 4L5, Canada
  • Diex Research Sherbrooke Inc.
    Sherbrooke, Quebec J1H 1Z1, Canada
  • Centre de Recherche Dermatologique du Quebec metropolitain (CRDQ)
    Quebec, G1V 4X7, Canada
  • ISA GmbH
    Berlin, 10789, Germany
  • Universitaetsklinikum Schleswig-Holstein
    Luebeck, 23538, Germany
  • Universitaetsklinikum Muenster
    Muenster, 48149, Germany
  • Universitaetsklinikum Tuebingen
    Tuebingen, 72076, Germany
  • Bacs Kiskun Megyei Korhaz, Bor es Nemibeteggondozo
    Kecskemet, 6000, Hungary
  • CRU Hungary Ltd., MISEK-CRU
    Miskolc, 3529, Hungary
  • Szegedi Tudomanyegyetem SzentGyorgyi Albert Klinikai Kozpont Borgyogyaszati es Allergologiai Klinika
    Szeged, 6720, Hungary
  • Allergo-Derm Bakos Kft.
    Szolnok, 5000, Hungary
09

References and documents

Publications

  • Gooderham MJ, Girolomoni G, Moore JO, Silverberg JI, Bissonnette R, Forman S, Peeva E, Biswas P, Valdez H, Chan G. Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial. Dermatol Ther (Heidelb). 2022 Sep;12(9):2077-2085. doi: 10.1007/s13555-022-00764-4. Epub 2022 Aug 7. PubMed 35933552 ↗
  • Blauvelt A, Boguniewicz M, Brunner PM, Luna PC, Biswas P, DiBonaventura M, Farooqui SA, Rojo R, Cameron MC. Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life. J Dermatolog Treat. 2022 Aug;33(5):2605-2613. doi: 10.1080/09546634.2022.2059053. Epub 2022 Jul 6. PubMed 35763326 ↗
  • Stander S, Bhatia N, Gooderham MJ, Silverberg JI, Thyssen JP, Biswas P, DiBonaventura M, Romero W, Farooqui SA. High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents. J Eur Acad Dermatol Venereol. 2022 Aug;36(8):1308-1317. doi: 10.1111/jdv.18170. Epub 2022 May 6. PubMed 35462428 ↗
  • Wojciechowski J, Malhotra BK, Wang X, Fostvedt L, Valdez H, Nicholas T. Population pharmacokinetic-pharmacodynamic modelling of platelet time-courses following administration of abrocitinib. Br J Clin Pharmacol. 2022 Aug;88(8):3856-3871. doi: 10.1111/bcp.15334. Epub 2022 Apr 11. PubMed 35342978 ↗
  • Wojciechowski J, Malhotra BK, Wang X, Fostvedt L, Valdez H, Nicholas T. Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis. Clin Pharmacokinet. 2022 May;61(5):709-723. doi: 10.1007/s40262-021-01104-z. Epub 2022 Jan 21. Erratum In: Clin Pharmacokinet. 2022 Apr;61(4):591. doi: 10.1007/s40262-022-01112-7. PubMed 35061234 ↗
  • Simpson EL, Silverberg JI, Nosbaum A, Winthrop KL, Guttman-Yassky E, Hoffmeister KM, Egeberg A, Valdez H, Zhang M, Farooqui SA, Romero W, Thorpe AJ, Rojo R, Johnson S. Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program. Am J Clin Dermatol. 2021 Sep;22(5):693-707. doi: 10.1007/s40257-021-00618-3. Epub 2021 Aug 18. Erratum In: Am J Clin Dermatol. 2021 Nov;22(6):905. doi: 10.1007/s40257-021-00638-z. PubMed 34406619 ↗
  • Silverberg JI, Thyssen JP, Simpson EL, Yosipovitch G, Stander S, Valdez H, Rojo R, Biswas P, Myers DE, Feeney C, DiBonaventura M. Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes. Am J Clin Dermatol. 2021 Jul;22(4):541-554. doi: 10.1007/s40257-021-00604-9. Epub 2021 May 5. Erratum In: Am J Clin Dermatol. 2021 Sep;22(5):739. doi: 10.1007/s40257-021-00634-3. PubMed 33954933 ↗
  • Simpson EL, Wollenberg A, Bissonnette R, Silverberg JI, Papacharalambous J, Zhu L, Zhang W, Beebe JS, Vincent M, Peeva E, Bushmakin AG, Cappelleri JC, Chen L, Sikirica V, Xenakis J. Patient-Reported Symptoms and Disease Impacts in Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 2b Study With Abrocitinib. Dermatitis. 2021 Oct 1;32(1S):S53-S61. doi: 10.1097/DER.0000000000000725. PubMed 33795561 ↗
  • Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C, Zhu L, Papacharalambous J, Vincent MS, Peeva E. Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial. JAMA Dermatol. 2019 Dec 1;155(12):1371-1379. doi: 10.1001/jamadermatol.2019.2855. Erratum In: JAMA Dermatol. 2020 Jan 1;156(1):104. doi: 10.1001/jamadermatol.2019.4551. PubMed 31577341 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Mar 2017, 11 months.

Results were first posted in May 2018, 1 year 2 months after primary completion.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 11 months is below that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2016
First posted
May 23, 2016
StartActual
Apr 2016
Primary completionActual
Mar 2017
CompletionActual
Apr 2017
Results first posted
May 16, 2018
Last update
May 2, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02780167
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 23, 2016
Start date
Apr 2016
Primary completion
Mar 2017
Completion
Apr 2017
Results posted
May 16, 2018
Last update
May 2, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abrocitinib

Start the discussion